Limited time 10% Bonus for indications of interest!
Indicate your interest:
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Example: if an investor reserves 100 shares, and subsequently confirms this reservation and purchases the 100 shares, such investor will receive an additional 10 shares of the company’s Series B Preferred Stock, for a total of 110 shares. “Reserving” shares is simply an indication of interest. There is no binding commitment for investors that reserve shares in this manner to ultimately invest and purchase the shares reserved of the company, or to purchase any shares of the company whatsoever.

Company Highlights

We believe we are on track to be the first company to market with an active milling navigated robot arm with 3D printed patient-optimized implants.  Now is the time for us to ramp the intensity and push even harder towards our mission.

Expect revenue in 2021

2 active distributors and expect sales of licensed implants

World-class team

Let by top surgeons and experts in robotics and medical technology

350 sq. ft. cadaver lab complete

Development and demo lab with dedicated robotics in 4,000 sq. ft. Austin facility

8 Patent Applications Filed

We believe we will be early to market with our novel technology and a Freedom to Operate on our knee implant

Have already raised $16.7M

We have been developing our technology since 2016 and now have the support of 6,793 investors

Solving Real Problems

it is estimated that up to one third of TKA recipients experience chronic pain postoperatively.

Joint replacement technology has, in many ways, remained the same for 40 to 50 years. Often crude and finicky instruments like saws and jigs are used to prepare the bone for geometric and rigid generic implants that don't accurately fit.  Insertions are often eyeballed and subject to proper surgeon execution.  We have designed the Monogram workflow for efficiency and unwavering accuracy.

50% of early revision total knee arthroplasties related to instability, malalignment or malposition, and failure of fixation.

Knees

Rate of re-admission:

7%-8%.

Approximately 50%-75% are surgical.

36%

Survey: 36% of TKA patients would not have undergone the surgery knowing what it did for them (10 years later).

1 in 5

1 in 5 patients are not satisfied with the results of their total knee replacement.

Potentially Preventable Reasons for revision Procedure
Mechanical Loosening
19%
Other Mechanical Problems
10%
Dislocation/instability
7%
Other mechanical complications
5%
Limited time 10% Bonus for indications of interest!
Indicate your interest:
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Example: if an investor reserves 100 shares, and subsequently confirms this reservation and purchases the 100 shares, such investor will receive an additional 10 shares of the company’s Series B Preferred Stock, for a total of 110 shares. “Reserving” shares is simply an indication of interest. There is no binding commitment for investors that reserve shares in this manner to ultimately invest and purchase the shares reserved of the company, or to purchase any shares of the company whatsoever.

Building Critical Infrastructure to Scale Growth

Executed agreements with 2 distributors and expect to sign more distributors in key markets.

We have licensed certain FDA approved, clinically well established implant components that will be integrated into our proprietary Monogram knee system. Monogram will leverage the testing and proven performance of these components (articulation, locking mechanisms, inserts) to focus on our novel tibial component and robotics.

Implants designed for uncemented stability.

Monogram implants rely on natural biologic fixation and are smaller, bone conserving, and more stable.

Implant

Monogram Results

Orthopedic implants are generic and indistinguishable.  The industry is using the same implant and instrument ideology that it has been for the past 50 years.  It's time to use technology to change the game.

Patient-optimized bone sparing press-fit implants

The leading generic equivalent had up to 270% more micromotion than Monogram

The cementless total knee market is expected to grow by $1.2BN from 2020 to 2024 (22% CAGR)

Approximately 95% of hip implants are press-fit
Will uncemented knee adoption follow the hip trend?
In a period of 10 years, the use of cement decreased from 54% to 4% in 2019. Similarly, we anticipate there could be a significant decrease in the use of cement in knee replacements over the next decade or so.
Tibia

Our Products

Implants Designed for Stability

Monogram implants are smaller, less invasive, and more stable.

Leading Generic

Poor fixation by design

Monogram

Optimized fixation

Monogram Results

Orthopedic implants are generic and indistinguishable.  The industry is using the same implant and instrument ideology that it has been for the past 50 years.  It's time to use technology to change the game.

up to 270%
more stable than generic equivalent
Independent micromotion testing conducted by leading orthopedic labs at UCLA and UNMC.

Better Vision

Tracking cameras directly mounted to the robot to mitigate line-of-sight issues.

Increased Range of Motion

Seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage the kinematic redundancy to avoid interoperative boundaries and optimize execution.

Active Navigated Milling

High-efficiency rotary cutting system to gently excavate the negative space for the patient-optimized implant.

Robotic Surgical Assistants

Monogram’s navigated surgical robot features several enhancements that will improve surgical experiences including:

Disrupting the Joint Replacement Market

$19.6B

Joint Replacement Market

Less than 65 yrs fastest growing demographic

Patients less than 65 years of age represent the fastest-growing population of TKR recipients, expected to account for more than 50% of knee replacement procedures by the year 2030

82% combined share

Four companies currently dominate the multi-billion dollar joint reconstruction market with an 82% combined share in knees

3.5 million

Annual Total Knee Replacement procedures by the year 2030

Over 1 million

Knee replacements in US annually

Stryker (Mako) is the only navigated robot arm on the market with a cutting end-effector. Monogram believes we will be the first active navigated arm on the market.

By 2027, approximately 50% of all knee procedures will be robotic, up from 11% in 2019

Significant Increases

in robotic adoption are expected over the next 5-10 years.
At least 50% of procedures will be robotic by 2027
Estimates for procedure volumes vary but TKA projections are generally between 935,000 and 1,260 and 1,260,000 by 2030

Monogram implants will not use cement! They will be cementless or press-fit.

Porous Coated for bone ingrowth ("Osseointegration")
No Cement Used

Developmental Milestones

Monogram is building the future of orthopedics one step at a time

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

WATCH VIDEO

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

The Technology Platform

Monogram Orthopaedics is developing a product solution architecture to enable mass personalization of orthopedic implants by linking 3D printing and robotics via automated digital image analysis algorithms.

The Robotics

Monogram’s navigated robot features several enhancements that will improve user experience compared to robots currently in use. Specifically, the Monogram robot will feature tracking cameras mounted directly on the robot to mitigate line-of-sight issues. The robot will feature seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage kinematic redundancy to avoid inoperative boundaries and optimize surgical execution. The robot will also utilize complex tracking capabilities for soft-tissue avoidance.

Our Implants

Monogram implants are designed such that cortical contact and stability are maximized while remaining insertable and designed to reconstruct the native patient anatomy as closely as possible. Monogram will commercialize the first patient specific hip and knee to address the primary clinical shortcomings of their generic counterparts.

The Technology Platform

Monogram Orthopaedics is developing a product solution architecture to enable mass personalization of orthopedic implants by linking 3D printing and robotics via automated digital image analysis algorithms.

The Robotics

Monogram’s navigated robot features several enhancements that will improve user experience compared to robots currently in use. Specifically, the Monogram robot will feature tracking cameras mounted directly on the robot to mitigate line-of-sight issues. The robot will feature seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage kinematic redundancy to avoid inoperative boundaries and optimize surgical execution. The robot will also utilize complex tracking capabilities for soft-tissue avoidance.

Our Implants

Monogram implants are designed such that cortical contact and stability are maximized while remaining insertable and designed to reconstruct the native patient anatomy as closely as possible. Monogram will commercialize the first patient specific hip and knee to address the primary clinical shortcomings of their generic counterparts.

The Plan

Monogram is building the future of orthopedics one step at a time

2017 Seed Round #1

$1,032,000 convertible note round.

Oct 12, 2017

First patent application published
UCLA Hip Studies

Q1 2018

Nebraska Knee Studies

2018 Seed Round #2

$1,148,000 convertible note round.

Q1 2019

3D Printing Mechanical Testing

Q1 2020

Strategic Engineering Hires
TKA Licensing Agreement

April 2020

$14,568,568 Series-A round

Q3 2020

Surgeon Advisory Board
Signed First Monogram Distributor

Q4 2020

First Monogram Cadaver Lab
15 Full-time Employees

August 2021

Exhibit Product System to American
Academy of Orthopaedic Surgeons (AAOS)

2021

Revenues
$30,000,000 capacity Series-B Close
Monogram Implant Submission
Monogram 2nd Gen Implants
  • Insertion with manual instruments & robotics
  • 510(k) Submission
  • Expecting to finalize design in 2020 - cadaver lab
  • Expecting to demo at AAOS in August 2021

2023

Monogram Robot Submission
Monogram Surgical Robot
  • Designed for Gen 2 implant
  • 510(k) Submission
  • Expecting to start formal V&V by Q3 2021
  • Expecting to demo at AAOS in August 2021
Navigated Robot System
2. Cutting System
3. Implants
4. Navigation Consumables
5. Cutting Tools
6. Software
Navigated Robot System
2. Cutting System
3. Implants
4. Navigation Consumables
5. Cutting Tools
6. Software

The Business Model

We believe that precision implants with precision insertion are the future of orthopaedics. Monograms principal competitive advantage will be our ability to produce customized, robotically inserted orthopaedic implants rapidly and at scale. The product solution architecture we are developing enables rapid fabrication and mass personalization of robotically inserted, patient specific orthopaedic implants.

Meet the Team

See Our Team

Douglas Unis, Md

Founder & Chief Medical Officer

Dr. Unis is a board-certified attending orthopedic surgeon for the Mount Sinai Health System and Chief of Quality Improvement for Mount Sinai West.

Benjamin Sexson - CEO

CFA, Chief Executive Officer

Prior to joining Monogram, Mr. Sexson served as the Director of R&D and Business Development at Pro-dex (ticker: PDEX). Mr. Sexson graduated with honors from Caltech in Mechanical Engineering and is a CFA Charterholder.

Paul Riss

CPA, MBA, INTERIM CFO

Experienced executive with a demonstrated history of completing SEC filings, focusing on the Securities Exchange Act of 1934 and Section 4(a)(6) of the Securities Act of 1933.  Currently serves as a Director for NetCapital and was a CPA with Ernst & Young.

Sherif Aly, P.hD.

VP Engineering

Sherif was instrumental to the development of the Mako Orthopedic Robot and Implant systems.  After the Mako acquisition, he was the Sr Director of Robotics Development Program Management, reporting to the VP of Robotics R&D, and was responsible for managing all Stryker Joint Replacement robotics development programs (over 250 engineers at 7 sites worldwide). Most recently, Sherif was the VP of Engineering and Regulatory Affairs at Xenex Disinfection Systems. 

Christopher Scifert, P.hD.

Director of Product Development Implants and Instruments

Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.

Richard Jackson

Director of Software

Before joining Monogram, Richard was a Software and Systems Engineering Manager at Biolase Inc., based in Irvine, CA.  Richard has over 20 years of software engineering experience, including experience in regulated industries, and has held various management roles.

Mark Cole

Director of Quality and Regulatory Assurance

Before joining Monogram, Mark was the Director, Quality and Product Development at Vigilant Biosciences Inc. Mark has over 20 years of experience, including experience in various Quality and Regulatory management roles.

Sophia Sangiorgio, PhD

Director, Orthopaedic Institute for Children

Laura Gilmour

Global Medical B. Development Manager at EOS NA

Matt DiCicco, M.S.

Robotics, MIT

Dr. Roshan Shah

Director of Complex Adult Hip and Knee Reconstruction at Columbia University

Robert Jamieson

Board Certified Orthopaedic Surgeon at The Orthopedic Specialty Center of Northern California

Dr. Matthew E. Heinrich

Total Joint Replacement Specialist at Orthopaedic Specialists of Austin

Darwin Chen

Associate Professor of Orthopaedics at Icahn School of Medicine at Mt Sinai

Dr. Gregory Catlett

Total Joint Replacement Specialist at Orthopaedic Specialists of Austin
Limited time 10% Bonus for indications of interest!
Indicate your interest:
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Example: if an investor reserves 100 shares, and subsequently confirms this reservation and purchases the 100 shares, such investor will receive an additional 10 shares of the company’s Series B Preferred Stock, for a total of 110 shares. “Reserving” shares is simply an indication of interest. There is no binding commitment for investors that reserve shares in this manner to ultimately invest and purchase the shares reserved of the company, or to purchase any shares of the company whatsoever.